Paladin Advisory Group’s GSK GSK Stock Holding History

Paladin Advisory Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-321	Closed	-$17.7K	–	366
2022 Q1	$17K	Buy	+321	New	+$17.4K	0.01%	218

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Paladin Advisory Group's GSK Position: Q2 2022 in Review

Paladin Advisory Group sold out of GSK (GSK) in Q2 2022, closing a stake of 321 shares — an estimated $17.7K sold.

Paladin Advisory Group first reported a position in GSK in Q1 2022 and held it in 1 quarter. The position peaked at $17K in Q1 2022. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Paladin Advisory Group reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
Paladin Advisory Group sold 321 GSK shares in Q2 2022, an estimated $17.7K.
Paladin Advisory Group first reported a position in GSK in Q1 2022 and held it in 1 quarter.
Paladin Advisory Group's GSK position peaked at $17K in Q1 2022.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Paladin Advisory Group's 13F filing for Q2 2022, filed 6 Jul 2022.